All In MedTech

Device Trial Radar · NCT07827287

Utility of the Perclose ProGlide™ Suture-Mediated Closure Device After Cardiologic Procedures Via the Femoral Vein Approach (Eight-Clover)

Utility of the Perclose ProGlide™ Suture-Mediated Closure Device After Cardiologic Procedures Via the Femoral Vein Approach ( Eight-CLOVER Trial)

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

May 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Ewha Womans University Mokdong HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ewha Womans University Seoul Hospital
First posted
Sep 18, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the clinical efficacy and safety of the Perclose ProStyle™ Suture-Mediated Closure Device in patients undergoing cardiologic procedures via a femoral vein approach using a sheath size of 8 French or larger.Patients receiving cardiac interventions-such as atrial fibrillation catheter ablation, leadless pacemaker insertion, atrial septal defect (ASD) patch closure, or left atrial appendage occlusion (LAAO)-will be randomly assigned in a 1:1 ratio to either the intervention group (using the Perclose ProStyle™ device for vascular closure) or the control group (using conventional manual compression or figure-of-eight suture).The primary outcome of the study is the time to ambulation after the procedure. Secondary outcomes include time to hemostasis, time to discharge eligibility, patient satisfaction scores, and the incidence of vascular complications within 30 days post-procedure.

Conditions

  • Atrial Fibrillation
  • Atrial Septal Defect
  • Vascular Closure Device

Interventions

  • Perclose ProStyle™ Suture-Mediated Closure SystemDevice

    Vascular closure device applied to the femoral vein access site immediately following sheath removal.

  • Conventional Hemostasis (Manual Compression or Figure-of-Eight Suture)Other

    Hemostasis achieved using standard manual compression or figure-of-eight suture technique at the femoral vein access site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to AmbulationTime frame: Up to 24 hours post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ewha Womans University Mokdong Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.